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Abstract: This subject-masked, randomized, active and placebo-controlled study compared 
subjects’ perceptions of two antibiotic ophthalmic drops. One hundred and twenty-ﬁ  ve healthy 
volunteers received two of the following solutions: moxiﬂ  oxacin 0.5% ophthalmic solution 
(Vigamox®, Alcon Laboratories, Inc., Ft Worth, TX, USA), azithromycin 1% in DuraSite® 
(AzaSiteTM, Inspire Pharmaceuticals, Inc., Durham, NC, USA), or Tears Naturale II® (Alcon 
Laboratories, Inc., Ft. Worth, TX, USA) in contralateral eyes. Immediately following instilla-
tion and at 1, 3, 5, and 10 minutes thereafter, subjects rated comfort, acceptability, and blurring 
on 0–10 point analog scales stating their preference of treatment. Among subjects receiving 
moxiﬂ  oxacin and azithromycin in contralateral eyes, 84% preferred moxiﬂ  oxacin. Moxiﬂ  oxacin 
was rated more comfortable and acceptable with less blurring than azithromycin (p   0.0001). 
These differences were observed in both the adult and pediatric populations. Ocular adverse 
events (redness, irritation, stinging, burning, dryness, itching and chemosis) were observed in 
18 (17.3%) eyes receiving azithromycin and 1 (1%) eye receiving moxiﬂ  oxacin. Moxiﬂ  oxacin 
was signiﬁ  cantly more tolerable than azithromycin in healthy adult and pediatric eyes. Toler-
ability and patient acceptance affect compliance; thus these data should be of signiﬁ  cance to 
the clinician.
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Introduction
Bacterial conjunctivitis is a common, acute, contagious disease characterized by 
inﬂ  amed conjunctiva with purulent mattering of the lids. Topical antibiotics have been 
shown to speed clinical recovery (Leibowitz et al 1981; Gigliotti et al 1984). Since 
cultures are rarely performed, the treatment is typically empiric with broad spectrum 
topical antibiotics (American Academy of Ophthalmology 2003). This practice is sup-
ported by studies previously showing clinical conjunctivitis is caused by a bacterial 
organism between 55% and 78% of the time (Buznach et al 2005; Patel et al 2007).
Moxiﬂ  oxacin 0.5% ophthalmic solution (Vigamox®, Alcon Laboratories, Inc., 
Ft Worth, TX, USA) is a fourth generation ﬂ  uoroquinolone currently indicated for 
13 isolates of bacterial conjunctivitis (Vigamox 2003). It is a broad spectrum, concentra-
tion-dependent, bactericidal antibiotic (Bryskier 2005; Wispelway 2005). Conversely, 
azithromycin is derived from the parent class of macrolides known to be bacteriostatic 
and time-dependent (Bryskier and Bergogne-Bérézin 2005; Carbon 1998). While it is 
suggested that concentration is a factor in the antibacterial effect of azithromycin, given 
the current high level of Gram-positive resistance patterns, this agent demonstrates 
a time-dependent, bacteriostatic effect. Azithromycin 1% formulated in DuraSite® 
(AzaSiteTM, Inspire Pharmaceuticals, Inc., Durham, NC, USA) is currently indicated for 
5 bacterial isolates (Azasite 2007). The persistent pace of evolution, however, indicates 
bacterial susceptibility to a systemic antibiotic may change over time (Chaudhry et al 
1999; Goldstein et al 1999; Alexandrakis et al 2000; Maguen and Morgan 2007). The Clinical Ophthalmology 2007:1(4) 520
Granet et al
clinical efﬁ  cacy of an antibiotic can also be undermined by 
patient compliance.
Compliance with topical therapy is often inadequate in 
ophthalmology (Shaya 2005; Bradshaw 2006). For instance, 
in glaucoma patients the rate of non-adherence to prescribed 
treatment regimens ranges from 17.3% to 44% (Kass et al 
1986; Kass et al 1987; Konstas et al 2000; Gurwitz et al 
1993). Comfort, convenience, and ease of administration 
would be expected to inﬂ  uence compliance with a speciﬁ  c 
eye drop dosing schedule (Winﬁ  eld et al 1990; Patel and 
Spaeth 1995). One study found subjects preferred eye drops 
requiring fewer instillations and with less blurring and 
stinging (Jampel et al 2003). The recommended treatment 
regimen for azithromycin 1% in DuraSite® is 9 doses/week 
(Azasite 2007) and the recommended treatment regimen 
for moxiﬂ  oxacin 0.5% is 21 doses/week (Vigamox 2003). 
However, the frequency of dosing is not the only variable, nor 
necessarily the most important variable affecting compliance. 
It has been recently suggested that “pain” and “irritation” 
scales could have important implications for compliance 
with ocular antibiotics (Donnenfeld et al 2004).
This study assessed other factors which may affect patient 
compliance including drop preference, comfort, acceptabil-
ity, blurring, residue, and sensation. The purpose of this study 
was to compare subjects’ perceptions of moxiﬂ  oxacin and 
azithromycin in healthy adult and pediatric subjects.
Subjects and methods
Subjects 9 years of age or older with normal ocular health 
were enrolled in this single center, single-visit, subject-
masked, randomized, active, and placebo-controlled study. 
To determine eligibility for the study, medical and ophthal-
mic histories were taken, best corrected ETDRS visual acuity 
(BCVA) was measured, and a slit lamp biomicroscopy exam 
was performed. All subjects were healthy volunteers with 
ETDRS visual acuity  0.3 LogMAR, who had not used 
contact lenses or ophthalmic medications recently (within 
5 days). Subjects had no recent history of disease (ocular or 
systemic) or ocular surgery. Written informed consent was 
obtained for each qualiﬁ  ed subject. Institutional review board 
approval was obtained from Coast IRB.
A trained technician instilled one drop of each study 
medication in the eyes of 125 healthy volunteers. Adult sub-
jects were randomized in a 3:1:1 ratio and pediatric subjects 
were randomized in a 5:1:1 ratio, according to the following 
treatment scheme:
•  One drop of moxiﬂ  oxacin HCL 0.5% ophthalmic solution 
(moxiﬂ  oxacin) in one eye and one drop of azithromycin 
1% in DuraSite® ophthalmic solution (azithromycin) in 
the fellow eye or
•  One drop of moxiﬂ  oxacin in one eye and 1 drop of Tears 
Naturale II® (placebo) (Alcon Laboratories, Inc, Ft Worth, 
TX, USA) in the fellow eye or
•  One drop of azithromycin in one eye, and 1 drop of pla-
cebo (Tears Naturale II®) in the fellow eye.
The following assessments were completed immediately after 
drop instillation and at 1 minute, 3 minutes, 5 minutes, and 
10 minutes following instillation. During instillation of the 
study medication subjects were asked not to touch the orbit 
of the eye in order to determine actual effects of the products 
as dosed on the ocular surface. Subjects were asked to use 
0–10 anchored analog scales to rate comfort (0 = very com-
fortable to 10 = very uncomfortable), acceptability (0 = very 
acceptable to 10 = very unacceptable), and blurriness (0 = no 
blurring to 10 = complete blurring) of each drop in each eye 
at each time point. Subjects were given a mirror and asked if 
they noticed any residue around their eyes (absent or present). 
Subjects were also asked to choose three words to describe 
how the drop felt in each of their eyes and which drop they 
preferred (their left eye drop or their right eye drop).
After drop comfort, acceptability, blurring, residue, and 
preference assessments had been completed at all 5 time 
points (0, 1, 3, 5, and 10 minutes post-instillation), BCVA and 
slit lamp biomicroscopy exams were performed. As a safety 
measure, BCVA and slit lamp results before and after drop 
instillation were compared. Adverse events, both elicited and 
observed, were monitored. The study was conducted in com-
pliance with Good Clinical Practices and the International 
Conference on Harmonization guidelines.
Chi-square analysis was used to compare the treatment 
preference between groups. Average comfort, acceptability 
and blurriness scores were compared using paired t-test in 
subjects receiving moxiﬂ  oxacin and contralateral azithromy-
cin, moxiﬂ  oxacin and contralateral placebo, and azithromy-
cin and contralateral placebo. In addition, a pooled analysis 
of all subjects receiving moxiﬂ  oxacin and azithromycin (ie, 
scores in all subjects receiving either antibiotic even when 
administered with contralateral placebo) was also performed 
and scores compared using paired t-test.
Results
Demographics
One hundred and twenty-ﬁ  ve subjects were enrolled and ran-
domly assigned to a treatment group; 84 subjects (34 adults 
and 50 children) received moxiﬂ  oxacin and contralateral 
azithromycin, 21 subjects (11 adults and 10 children) received Clinical Ophthalmology 2007:1(4) 521
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moxifloxacin and contralateral placebo, and 20 subjects 
(10 adults and 10 children) received azithromycin and contra-
lateral placebo. Sixty-one percent of subjects were female and 
97% were Caucasian. The treatments groups were balanced 
for gender and race distribution.
Overall preference
When asked if they preferred the drop in their left eye or the 
drop in their right eye, more subjects chose the eye instilled 
with moxiﬂ  oxacin (p   0.0001). In both pediatric and adult 
subjects receiving moxiﬂ  oxacin and azithromycin simultane-
ously there was a signiﬁ  cant preference for moxiﬂ  oxacin over 
azithromycin at every time point (p   0.0001 and p   0.0002, 
respectively). An average of 84% of all subjects and 82% of 
pediatric subjects preferred moxiﬂ  oxacin over azithromycin 
(Figure 1). Subjects who received azithromycin and contralat-
eral placebo (n = 20) signiﬁ  cantly preferred placebo at most 
(4/5) time points (p   0.01). For subjects receiving moxiﬂ  oxa-
cin and contralateral placebo (n = 21) there was no difference 
between treatments in terms of preference at any time point.
Comfort, acceptability, and blurriness
In subjects receiving moxiﬂ  oxacin and azithromycin simul-
taneously, moxiﬂ  oxacin was signiﬁ  cantly more comfort-
able (p   0.0001), acceptable (p   0.0001), and resulted 
in less blurring (p   0.0001) than azithromycin at every 
time point (Figures 2–4). These statistical differences were 
seen in both the pediatric and adult populations (p   0.02). 
Pooled analysis comparing antibiotics (ie, moxiﬂ  oxacin 
and azithromycin eyes from subjects receiving contralateral 
placebo and subjects receiving both antibiotics contralater-
ally) also demonstrated favorable comfort, acceptability, 
and blurriness scores for moxiﬂ  oxacin (p   0.0001 for each 
parameter) over azithromycin.
Comparison of the comfort, acceptability, and blurriness 
scores for subjects receiving moxiﬂ  oxacin with contralateral 
placebo demonstrated no difference in comfort scores between 
moxiﬂ  oxacin and placebo at 4 of the 5 time points. Further-
more, there were no differences in acceptability or blurriness 
scores between moxiﬂ  oxacin and placebo at any time point. 
In subjects receiving azithromycin with contralateral placebo, 
azithromycin was signiﬁ  cantly less comfortable (p   0.003) 
and acceptable (p   0.03) compared to placebo at every time 
point. Azithromycin also resulted in blurred vision signiﬁ  -
cantly more (p   0.02) than placebo at every time point.
Drop descriptors
Subjects were asked to describe how each drop felt with three 
words. Descriptors were categorized as positive and negative. 
If the subject thought the drop was “comfortable”, “cool”, 
“refreshing”, “smooth”, or “soothing”, that was considered 
a positive indicator of tolerability. If the subject thought the 
drop was “achy”, “burning”, “gritty”, “irritating”, “sticky”, 
“ﬁ  lmy”, “thick”, or “stinging”, that was considered a nega-
tive indicator of tolerability. The percentages included in 
Figure 5 represent the relative frequency a certain type of 
descriptor was used within each of the antibiotic treatment 
groups. A greater percentage of negative descriptors were 
reported with azithromycin compared to moxiﬂ  oxacin.
Residue
Subjects were given a mirror and asked if they noticed any 
residue around their eyes. Residue was categorized as either 
“absent” or “present.” Residue was more frequently seen 
around eyes which received azithromycin (27.4%) compared 
to eyes which received moxiﬂ  oxacin (4%) (p   0.0001). 
The difference in residue incidence among pediatric subjects 
receiving both antibiotics was signiﬁ  cant (p   0.04) at all 
time points (residue was present in 28.4% of eyes receiving 
azithromycin and 4% of eyes receiving moxiﬂ  oxacin). Among 
adult subjects, the difference was signiﬁ  cant (p   0.03) at 
most (3/5) time points.
Safety
Mild post-instillation changes were observed during slit 
lamp examinations. Twenty-seven ocular adverse events 
were observed in 19 subjects during the study, 6 among 
adult subjects and 13 among pediatric subjects. One subject 
receiving moxiﬂ  oxacin experienced 2 ocular adverse events 
and 18 subjects receiving azithromycin experienced 25 
adverse events (Table 1). Some of the adverse events were 
similar to the negative descriptors observed during the study 
Figure 1 Preference among subjects receiving moxifloxacin or azithromycin. 
(A) Preference for all subjects (n = 84) who received both antibiotics. (B) Preference 
for pediatric subjects (n = 50) who received both antibiotics. Pie charts based on an 
average of subjects at each visit who preferred either agent. Chi-square test comparison 
at each visit was statistically signiﬁ  cant, p   0.0001.
Moxifloxacin Azithromycin
16% 18%
84% 82%
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(ie, burning, stinging, irritation). One non-ocular adverse 
event was observed in a subject who received both antibiotics 
(post-nasal drip).
Discussion
In this study results for our primary endpoints were statisti-
cally in favor of moxiﬂ  oxacin without a single dissenting 
data point. In every population signiﬁ  cantly more subjects 
preferred moxiﬂ  oxacin over azithromycin. Moxiﬂ  oxacin was 
more comfortable and acceptable to subjects and resulted in 
less blurred vision than azithromycin. These differences were 
observed in both the adult and pediatric populations. Unlike 
azithromycin which was generally less tolerable than placebo, 
moxiﬂ  oxacin was similar to placebo in tolerability.
Formulation differences between moxifloxacin and 
azithromycin may explain the differences in tolerability mea-
sures. Moxiﬂ  oxacin is self-preserved at an approximate pH of 
6.8, while azithromycin is preserved with 0.003% benzalko-
nium chloride (BAK) at a pH of approximately 6.3. Solutions 
which are more acidic than average tear ﬁ  lm (pH 7.35) may 
induce ocular discomfort (Bartlett and Jaanus 1995). For the 
azithromycin formulation, BAK may affect drop tolerability 
(Furrer et al 2002). In addition, the DuraSite® component in 
the azithromycin formulation may increase the length of time 
Figure 3 Average acceptability score vs. time among subjects receiving moxiﬂ  oxacin or azithromycin. (A) Average acceptability scores for all subjects (n = 84) who received 
both antibiotics. (B) Average acceptability scores for pediatric subjects (n = 50) who received both antibiotics. Errors bars indicate standard error of the mean.
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Figure 2   Average comfort score at each time point among subjects receiving moxiﬂ  oxacin or azithromycin. (A) Average comfort scores for all subjects (n = 84) who received 
both antibiotics. (B) Average comfort scores for pediatric subjects (n = 50) who received both antibiotics. Errors bars indicate standard error of the mean.
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BAK is in contact with the corneal surface. DuraSite® may also 
be responsible for the negative acceptability and blurring attri-
butes found in this study. Both antibiotics have approximately 
the same osmolality (290 mOsm/kg), which is within the limits 
of normal tear osmolality (ie, between 280 and 330 mOsm/kg) 
(Farris et al 1981; Craig and Tomlinson 1995).
At 10 minutes post-instillation, comfort and acceptability 
scores for azithromycin were higher than previous time 
points, indicating less comfort and acceptability over time 
(Figures 2 and 3). It is possible that the relative discomfort 
seen at the 10 minute time point is related to viscosity 
differences between azithromycin in DuraSite® and the other 
study drops. Studies of artiﬁ  cial tears indicate increased 
viscosity in eye drops increases the incidence of blurred 
vision, stickiness, and eyelash residue (LaMott et al 2002; 
Noecker 2006). In this study, we found azithromycin was 
frequently described with viscosity-related words like 
“sticky”, “thick”, and “ﬁ  lmy” (mentioned 33.1%, 30.2%, and 
26.7% of the time, respectively, compared to 1.7%, 1.2%, 
and 4.8% for moxiﬂ  oxacin). In addition, we found subjects 
receiving azithromycin more frequently noticed residue 
around their eyes compared to the other study drops.
Complaints from subjects after the last (10 minute) time 
point were considered adverse events. Mild ocular complaints 
between time points (ie,  10 minutes post-instillation) were 
considered drop descriptors, not adverse events. Some of 
the negative words used frequently to describe azithromy-
cin drops within 10 minutes of instillation were similar to 
adverse events observed in eyes treated with azithromycin 
after 10 minutes post-instillation. This suggests some adverse 
events were not aberrations but instead persistent symptoms 
of ocular sensations. Overall, the incidence of ocular adverse 
events was higher in azithromycin-treated eyes (17.3%) than 
moxiﬂ  oxacin-treated eyes (1.0%).
Missing doses of prescribed eye drops can undermine 
the clinical efﬁ  cacy of ophthalmic anti-infective treatment 
(Konstas et al 2000). Many variables affect compliance, 
for example: gender, number of prescribed medications, 
and treatment cost (Gurwitz et al 1993; Konstas et al 2000; 
Patel and Spaeth 2005). Additionally, some subjects may 
be unintentionally noncompliant because they do not instill 
drops correctly (Winﬁ  eld et al 1990; Konstas et al 2000). 
Compliance can also be affected by the tolerability of an agent 
with less tolerable agents increasing patient noncompliance. 
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Figure 4 Average blurring score vs. time among subjects receiving moxiﬂ  oxacin or azithromycin. (A) Average blurring scores for all subjects (n = 84) who received both 
antibiotics. (B) Average blurring scores for pediatric subjects (n = 50) who received both antibiotics. Errors bars indicate standard error of the mean.
Table 1 Reported ocular adverse events (AEs)
Type of ocular AE  Incidence among   Incidence among 
  eyes receiving   eyes receiving 
 azithromycin  moxiﬂ  oxacin
  n (%)  n (%)
Redness  4 (3.8%)  1 (1.0%)
Irritationa 4  (3.8%)  -
Stinginga 7  (6.7%)  -
Burninga 6  (5.8%)  -
Dryness 1  (1.0%)  -
Itching   1 (1.0%)  -
Chemosis   2 (1.9%)  1 (1.0%)
Total number of eyes  
with ocular AEsb  18 (17.3%)  1 (1.0%)
aIndicates adverse events also reported as negative descriptors during the study. 
Irritation was reported as a negative descriptor in 23.1%, stinging in 21.2%, and 
burning in 12.4% of subjects receiving azithromycin.
b8 patients had 2 AEs in the same eye (i.e. 27 total ocular AEs in 19 eyes). 
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In the present study, azithromycin was signiﬁ  cantly less 
comfortable or acceptable than moxiﬂ  oxacin in the eyes of 
healthy volunteers. In diseased eyes (inﬂ  amed eyes with 
vascular dilation and mucopurulent discharge) it is also 
expected that the tolerability of both antibiotics would be 
even worse.
Compliance is also affected by dosing of a medication. 
The recommended treatment course for azithromycin is 
only 9 drops/week and the recommended treatment course 
of moxiﬂ  oxacin is 21 drops/week. Agents requiring fewer 
doses may be expected to result in greater compliance; 
however, less frequent dosing should be considered in light 
of the drug’s tolerability. If an agent is not well tolerated, 
the less frequent dosing regimen may not be advantageous. 
In addition, ocular tolerability may indirectly affect the 
efﬁ  cacy of an antibiotic drop for current and future patients. 
The package insert for azithromycin 1% warns “skipping 
doses or not completing the full course of therapy may 
decrease the effectiveness of the immediate treatment and 
increase the likelihood that bacteria will develop resistance” 
(Azasite 2007). This concern regarding skipping a dose 
becomes more important for azithromycin where each 
drop represents 11% of the full treatment. Conversely, 
the threat of resistance would be expected to be less for 
moxiﬂ  oxacin where one missed dose only represents 4.7% 
of full treatment.
In conclusion, 84% of subjects receiving moxiﬂ  oxacin 
and azithromycin prefer moxiﬂ  oxacin drops. Tolerability 
endpoints provide a number of possible explanations for 
this preference. The moxiﬂ  oxacin drop is consistently more 
comfortable and more acceptable than the azithromycin 
drop and produces less blurring than the azithromycin 
drop. Azithromycin is also more frequently characterized 
with negative descriptors within 10 minutes of instillation 
and induces ocular adverse events after 10 minutes 
post-instillation more frequently (17.3% for azithromycin-
treated eyes, compared to 1% of moxiﬂ  oxacin-treated eyes). 
Since tolerability is expected to affect compliance, especially 
in children, these data are clinically important and suggest 
that moxiﬂ  oxacin should be the preferred therapy for the 
treatment of bacterial conjunctivitis.
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